Real Life of Aflibercept In FraNce: oBservatiOnnal Study in Wet AMD

Overview

The purpose of this study is to collect real-life data on patients with wet age related macular degeneration (AMD) for whom treatment with Eylea was initiated

Full Title of Study: “A Retrospective and Prospective Non-interventional Open Label Study to Assess the Real Life of Treatment-naive Patients With Wet Age-related Macular Degeneration in Routine Clinical Practice in France and Starting an Anti VEGF Therapy With Aflibercept”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Other
  • Study Primary Completion Date: April 17, 2019

Detailed Description

The study is both retrospective and prospective to collect local real life data on patients under routine treatment. The observation period starts on January 2014. Patients who have received the 1st injection with Eylea from January 2014 will be enrolled. Patients will be followed up for a period of 48 months or until it is no longer possible

Interventions

  • Drug: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
    • Administration by intravitreal injection

Arms, Groups and Cohorts

  • Cohort 1
    • According to the recommendations of the Summary of Product Characteristics (SmPC)

Clinical Trial Outcome Measures

Primary Measures

  • Change in the measurement of best-corrected visual acuity (BCVA) from baseline to 12 months.
    • Time Frame: Baseline to 12 months
    • As assessed by Early Treatment Diabetic Retinopathy Study (ETDRS) method or any visual logarithmic scale

Secondary Measures

  • Change in Best Corrected Visual Acuity (BCVA) during the second year and until the fourth year of treatment versus the initial visit
    • Time Frame: Baseline to 2 year, 3 year, 4 year
  • Percentage of patients who experienced a gain in BCVA, from initial visit to each follow-up visit (letter score of ≥ 0 letters, ≥ 5 letters, ≥ 10 letters, ≥ 15 letters)
    • Time Frame: Baseline to 1 year, 2 year, 3 year, 4 year
  • Percentage of patients losing fewer than 15 letters from the initial visit visual acuity at each follow-up visit
    • Time Frame: Baseline to 1 year, 2 year, 3 year, 4 year

Participating in This Clinical Trial

Inclusion Criteria

  • Patient with a diagnosis of wet AMD will be enrolled after the decision for treatment with Aflibercept (Eylea) has been made – Patient with 1st injection of Eylea from 01 January 2014 until 30 April 2015 will be enrolled – Prior/current treatment with any anti-VEGF intravitreal injections or macular laser (laser and/or visudyne/PDT) in the fellow eye is allowed – Man or woman aged 18 years or more – Patient who has been given appropriate information about the study objectives and procedures and who has given his/her written, informed consent; Exclusion Criteria:

  • Patient with another retinal disease: diabetic retinopathy, diabetic macular oedema (DME), myopic choroidal neovascularization, retinal vein occlusion (RVO), central serous chorioretinopathy (CSC), angioid streaks – Patient who does not meet the local indication criteria for Eylea treatment.Contraindications listed in the Summary of Product Characteristics (SmPC) must be taken into account – Patient who has previously been treated with any macular laser (laser and/or visudyne/PDT) or any anti-VEGF intravitreal injections for the study eye – Patient taking part in an interventional study at the time of enrolment.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Bayer
  • Collaborator
    • Regeneron Pharmaceuticals
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Bayer Study Director, Study Director, Bayer

Citations Reporting on Results

Cohen SY, Dominguez M, Coscas F, Faure C, Baillif S, Oubraham H, Kodjikian L, Weber M; RAINBOW study investigators. Final 4-year results of the RAINBOW real-world study: intravitreal aflibercept dosing regimens in France in treatment-naive patients with neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2023 Apr;261(4):959-969. doi: 10.1007/s00417-022-05900-6. Epub 2022 Nov 18.

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.